ABSTRACT
Pain and abnormal spermatogenesis are among symptoms deteriorating quality of life in patients with chronic prostatitis. Rectal suppositories vitaprost have no side effects, relieve pain, correct spermatogenesis. The effect of vitaprost treatment persists for 3 months and longer. Prostatic arteries embolization with vitaprost suppositories as preoperative preparation is a good alternative to surgical treatment in patients with prostatic adenoma.
Subject(s)
Embolism/drug therapy , Peptides/administration & dosage , Prostatic Hyperplasia/drug therapy , Prostatitis/drug therapy , Administration, Rectal , Adult , Chronic Disease , Embolism/diagnostic imaging , Embolism/physiopathology , Humans , Male , Peptides/adverse effects , Prostatic Hyperplasia/diagnostic imaging , Prostatic Hyperplasia/physiopathology , Prostatitis/diagnostic imaging , Prostatitis/physiopathology , Suppositories , UltrasonographyABSTRACT
Our studies of afala in patients with prostatic adenoma demonstrate that afala reduces irritative disorders of urination. Effect of this drug is seen in 98.3% patients during 4 weeks of its use. In longer intake the effect becomes stronger. The dose of 6 tablets a day significantly improves life quality. Three times a day dose is more effective in elimination of nicturia, enhances urine flow rate. Thus, choice of afala dose depends on the symptoms. Afala is indicated for prophylaxis in patients with initial stage of prostatic adenoma and as an alternative to expectation policy.
Subject(s)
Antibodies/therapeutic use , Prostate/drug effects , Prostatic Hyperplasia/drug therapy , Urination Disorders/prevention & control , Aged , Antibodies/administration & dosage , Drug Administration Schedule , Humans , Male , Middle Aged , Organ Size/drug effects , Prostate-Specific Antigen/blood , Prostate-Specific Antigen/immunology , Prostatic Hyperplasia/complications , Quality of Life , Severity of Illness Index , Surveys and Questionnaires , Treatment Outcome , Urination Disorders/etiologyABSTRACT
Naiz (nimesulid) was given to 46 patients (age 24-52 years) with chronic abacterial prostatitis suffering from chronic pelvic pain syndrome (CPPS) which appeared from 20 to 3 years before the treatment. Microscopy of prostatic secretion showed normal count of leukocytes. Transrectal ultrasound investigation with dopplerography has found normal echostructure of the prostate but blood flow parameters were subnormal. Naiz was given in a dose 100 mg (1 tablet) twice a day for 15-20 days. The treatment relieved pain in 68-87% patients (mean 77.5%). The control ultrasound investigation detected much better circulation. Quality of life improved significantly. Side effects were mild. The effect persisted for 3 months of the follow-up. Thus, the addition of such nonsteroid antiinflammatory drug as naiz (nimesulid) to treatment of patients with chronic abacterial prostatitis is justified. The drug improves quality of life, induces side effects rarely and can be used for a long time with a persistent efficacy.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Pelvic Pain/complications , Prostatitis/complications , Prostatitis/drug therapy , Sulfonamides/therapeutic use , Adult , Analgesics/adverse effects , Analgesics/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Chronic Disease , Drug Therapy, Combination , Humans , Leukocyte Count , Male , Middle Aged , Prostate/diagnostic imaging , Quality of Life , Sulfonamides/adverse effects , Syndrome , Treatment Outcome , UltrasonographyABSTRACT
The paper analyzes treatment outcomes in 72 patients with chronic pyelonephritis in the phase of active inflammation. The patients have received combined therapy including laser blood radiation to correct hemostatic defects. The latter manifested as DIC syndrome resistant to antibacterial treatment. Attempts to apply transcutaneous laser radiation (TLR) and intravascular laser radiation (ILR) showed that DIC syndrome may be cured only in the combined use of the above modalities.
Subject(s)
Blood Coagulation Disorders/therapy , Laser Therapy , Pyelonephritis/therapy , Blood Coagulation Disorders/blood , Chronic Disease , Combined Modality Therapy , Hemostasis , Humans , Pyelonephritis/blood , Remission InductionABSTRACT
The trial entered 41 patients with chronic renal failure. Group I (15 patients) received conventional therapy involving infusion detoxication, antibiotics, immunostimulators, anabolic agents. 26 patients of group II in addition to standard therapeutic measures underwent plasmapheresis. The effect was assessed by immunological and renal function parameters. Group I patients have benefited from conventional treatment, but signs of immunodeficiency remained: B-lymphocyte, IgG and IgA levels were lowered and elevated, respectively. Patients of group II improved clinically, got rid of uremia and immunodeficiency.
Subject(s)
Immune System Diseases/therapy , Kidney Failure, Chronic/therapy , Pyelonephritis/therapy , Chronic Disease , Combined Modality Therapy , Female , Humans , Immune System Diseases/etiology , Immune System Diseases/immunology , Kidney/abnormalities , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/immunology , Male , Plasmapheresis , Prostatic Hyperplasia/complications , Prostatic Hyperplasia/immunology , Prostatic Hyperplasia/therapy , Pyelonephritis/complications , Pyelonephritis/immunology , Urinary Calculi/complications , Urinary Calculi/immunology , Urinary Calculi/therapyABSTRACT
A total of 83 patients with chronic renal failure (CRF) at azotemia stage (S. I. Riabov's classification) complicating pyelonephritis were treated: 19 patients received symptomatic standard therapy (group 1), 29 patients received combined therapy with enterosorption (group 2), 35 patients received combined treatment with plasmapheresis (group 3). The efficacy of the treatments was controlled by platelet tests (platelet, coagulative hemostasis, fibrinolytic plasma activity) and parameters of kallikrein-kinin system. Treatment results in group 1 are characterized as poor: insignificant improvement of uremia, DIC syndrome against unchanged inhibition of kallikrein-kinin system. Group 2 patients achieved moderate response: uremia reduced to normal azotemia values, DIC syndrome and inhibition of kallikrein-kinin system reduced. Patients of group 3 got disappeared DIC syndrome and normal kallikrein-kinin system against high azotemia.
Subject(s)
Enterosorption , Hemostasis , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/therapy , Plasmapheresis , Blood Coagulation Tests , Combined Modality Therapy , Disseminated Intravascular Coagulation/blood , Disseminated Intravascular Coagulation/therapy , Enterosorption/methods , Evaluation Studies as Topic , Humans , Plasmapheresis/methods , Remission Induction , Uremia/blood , Uremia/therapyABSTRACT
The paper presents the results of plasmapheresis inclusion into a combined therapy of pyelonephritis. Out of 79 patients treated, 42 had urosepsis, 25 developed pyelonephritis in pregnancy, 12 had complicating chronic renal failure. Uroseptic patients were examined for hemostasis, the rest for immune status. There were symptoms of DIC syndrome in the former and immunity suppression in the latter. After the combined therapy with plasmapheresis, latent hypercoagulation and intoxication disappeared, uroseptic manifestations reduced. The above treatment of pregnancy pyelonephritis stopped inflammation, promoted activation of the immune system. In patients with chronic renal failure adjuvant plasmapheresis enhanced cellular and humoral immunity, neutrophil function, the number of middle-size molecules in the blood diminished. The latter improved renal function in decreasing uremia.
